



The
Patent
Office

19

PCT/GB 99/02517
JULY 1999



INVESTOR IN PEOPLE

6039/2317

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office
Concept House
Cardiff Road
Newport
South Wales

NP10 8QQ 17 SEP 1999

WIPO

PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.


In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.


Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated 10 August 1999



THIS PAGE BLANK (USPTO)



Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

1. Your reference

IPD/P1209

2. Patent application number

(The Patent Office will fill in this part)

23 JUL 1998

9815933.8

3. Full name, address and postcode of the or of each applicant (underline all surnames)

The Secretary of State for Defence
Defence Evaluation and Research Agency
Ively Road, Farnborough, Hampshire
GU14 0LX

Patents ADP number (if you know it)

7349996001

If the applicant is a corporate body, give the country/state of its incorporation

GB

4. Title of the invention

Detection Method

5. Name of your agent (if you have one)

A O Bowdery

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

D/IPR
Procurement Executive
Poplar 2
MOD Abbey Wood # 19
Bristol
BS34 8JH

Patents ADP number (if you know it)

6878169001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

priority application number
(if you know it)

Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number or earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right if to grant of a patent required in support of this request? (Answer 'Yes' if:

yes

- a) any applicant named in part 3 is not an inventor, or
 - b) there is an inventor who is not named as an applicant, or
 - c) any named applicant is a corporate body.
- See note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form.
Do not count copies of the same document

Continuation sheets of this form

Description 8 /

Claim(s) 3 /

Abstract 1 /

Drawing(s) 3 + 3 - 10

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77) 1 /

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

11.

I / We request the grant of a patent on the basis of this application.

S R SKELTON

Signature

S R Skelton

Date 21/07/98

12. Name and daytime telephone number of person to contact in the United Kingdom

P HILL 0117 9132865

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent of the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- a) If you need help to fill in this form or have any questions, please contact the Patent Office on 0645 500505.
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) If you have attached 'Yes' Patents Form 7/77 will need to be filed.
- e) Once you have filled in the form you must remember to sign and date it.
- f) For details of the fee and ways to pay please contact the Patent Office.

Detection Method

The present invention relates to a method of detecting specific target DNA sequences, and in particular to the products of amplification reactions, as well as to reagents and apparatus used in that method.

Many methods are known in order to detect the presence of particular target DNA sequences in a sample. A substantial proportion of these methods require that the DNA is denatured to single stranded form and then this sequence is hybridised or otherwise allowed to bind to a labelled sequence specific probe.

The target sequences are frequently subjected to amplification reactions, for example the polymerase chain reaction or the ligase chain reaction, in order to increase the amount of the target sequence to detectable levels.

Other methods of detecting sequences include the use of intercalating dyes which are incorporated into the sequences during the amplification reaction. However such methods are relatively non specific as the dyes will intercalate with any amplification product, even if they are the result of non-specific amplification products.

25

Other assays such as the TAQMANTM assay utilise complex probes which include reporter and quencher moieties during the course of the amplification process. These probes hybridise to single stranded target sequences during the amplification reaction and are then digested by the enzymes carrying out the reaction. The relationship between quencher and reporter molecule of the probe produces a signal which can be monitored. The probes used in this case however, are complex and expensive.

It is known that peptide nucleic acids will strand invade DNA at purine rich sites to form triplex structures (P.E. Nielson et al., Science, 1991, 254, p1497-1506, Turney D.Y. et al., Proc. Natl. Acad. Sci. USA, 1993, 90, 1667-1670). The mechanism by which this is effected is illustrated diagrammatically hereinafter in Figure 1.

The applicants have found that this phenomenon can be used in detection of target DNA sequences.

10

A method for detecting the presence of a target nucleic acid sequence in a sample, said method comprising

- (a) amplifying said target nucleic acid so that the product of the amplification reaction includes a purine rich region,
- (b) contacting the sample with a peptide nucleic acid able to bind to at least a portion of said target sequence; and
- (c) detecting the presence of triplex DNA structures.

20 The method enabling the direct detection of target sequences, for example amplification products without the usual denaturation step required for duplex formation with a nucleic acid probe.

25 The expression "purine rich region" means that the sequence is suitable for strand invasion by a peptide nucleic acid (PNA). Such regions suitably contain at least four consecutive purine residues.

30 The reaction in step (a) above is suitably effected in the presence of a buffer, and preferably a low salt buffer for example containing 50mM or less of salt as this favours triplex formation as compared to DNA:DNA duplexes. Furthermore, the pH of the buffer used will depend on the precise nature of the PNA

employed. If C's are used in the PNA strand to strand invade G's on duplex DNA, careful consideration has to be given to the pH of the buffer as the C involved in forming the Hoogsteen base-pair needs to be protonated, requiring a buffer of low pH, for example of less than 4.5.

The peptide nucleic acid used in the method of the invention may be single stranded or it may be bis-PNA. Preferably, the peptide nucleic acid used in the method is a bis-PNA as this results is a faster strand invasion process and a more stable triplex product.

Bis-PNA will comprise of two anti-parallel strands joined by a hydrophilic linker. One strand will be designed for Watson-Crick recognition of DNA within the target sequence, and the other strand is designed for Hoogsteen recognition of a PNA-DNA duplex. Such acids will be optimal for PNA₂DNA triplex stability and thus enhance strand-displacement binding to double-stranded DNA.

Peptide nucleic acids used will suitably contain a sequence of poly-T's or poly-C's.

The target nucleic acid is first subject to an amplification reaction such as the polymerase chain reaction (PCR) or ligase chain reaction (LCR), preferably PCR. The product may be exposed to the peptide nucleic acid during or after the amplification reaction, but is preferably exposed to the peptide nucleic acid after completion of the amplification reaction.

Where the target nucleotide sequence contains or is selected such that it contains a purine rich region, the method can be carried out directly. Where such regions do not exist in the target sequence, they may be introduced during the amplification

reaction. In this case, the amplification will be effected using one or more primers which comprise a plurality of pyrimidines, suitably at the 5' end thereof. This region will chain extend during the extension phase of the amplification (as illustrated in Figure 2 hereinafter). The 3'-end of both amplified strands of the amplification obtained using these primers should now contain the purine rich sites. Indeed, PCR products, that were tagged in this manner, have been cloned and sequenced and were found to have the poly-purine stretches incorporated at their 3' end. This ensures that a suitable PNA binding purine rich region is contained within the amplification product.

Primers of this sort form a further aspect of the invention.

The triplex formed may be detected using various methods in step (b). For example, gel retardation methods may be used. When the product is subjected to gel electrophoresis, for instance on a non-denaturing polyacrylamide gel, and then stained using conventional reagents such as ethidium bromide, the presence of a retarded triplex fraction can be observed.

This method however is relatively slow. Furthermore, comparison with a similar sequence which is not in the form of a triplex is required as a standard.

Preferably therefore, the detection is effected using a capture assay. The capture agent in this case is suitably the PNA sequence which is immobilised on a support. The sample is then contacted with the support whereupon any target sequence present will become associated with the PNA on the surface. It can then be detected using any of the known techniques.

In a particularly preferred embodiment, the support is a waveguide of a detection device which operates using evanescent wave detection. An example of such a device is a surface plasmon resonance detector. This allows the direct and rapid
5 detection of target nucleotide sequence within a sample.

Thus a product of the amplification reaction is simply allowed to flow over the waveguide of such a detector and the presence of an amplicon can be detected in something approaching "real
10 time".

In a further aspect, the invention provides a kit for use in the method of the invention. These kits suitably comprise a PNA designed to form a triplex with a target DNA. Optionally also,
15 it may contain primers which can be used in the amplification of the target DNA, in particular primers which are 5'-tagged with pyrimidines.

The kit may also comprise a waveguide of a evanescent wave
20 detector and particularly a surface plasmon resonance detector having supported thereon, the peptide nucleic acid which specifically binds a target DNA sequence.

The invention will now be particularly described by way of
25 example with reference to the accompanying diagrammatic drawings in which:

Figure 1 illustrates diagrammatically PNA:DNA triplex formation;

30 Figure 2 illustrates diagrammatically the incorporation of purine rich regions into an amplification product, using 5'-tagging of primers with polyamidine sequences; and

Figure 3 illustrates triplex formation on the surface of a surface plasmon resonance detector.

5 Example 1

Triplex Formation

The ability of PNA to form triplex structures with PCR products has been demonstrated using gel retardation studies. Two PCR products were chosen for study. One has a sequence capable of forming triplexes with a PNA probe i.e. contains poly-A sites.

PCR82

5'

ATAAATACAACCAACAAAATAAATAGTCATAAAATTGTATACATTAGCAATGCATACC
15 ACAAAGTTCTAAGTACTAAAATAT 3' (SEQ ID NO 1)

The other does not contain poly-A sites and acts as a negative control.

20 PCR 175

5'

GCGAAACGGAACATAGCCCAAACCAAGAGGCTTGCCTCTTGGGGTTGTAGGACATTCT
ATACGGAGTTACAAAGGAAGCAGGTAGACGAAGCGACCTGGAAAGGTCCGTCGTAGAGGGTAAC
AACCCCGTAGTCGAAACTTCGTTCTCTCTTGAATGTATCCTGAGTACGGCGGAACACGTGAAA
25 3' (SEQ ID NO 2)

Two types of PNA probe were used, one was a linear sequence and contains a sequence of poly-T's

30 PNA057

N TTTTCCTTCCCTTTT C (SEQ ID NO 3)

The other, a bis-PNA of the same linear sequence but composed of two anti-parallel strands joined by a hydrophilic linker. One

strand was designed for Watson-Crick recognition of DNA and the other strand is designed for Hoogsteen recognition of a PNA-DNA duplex and should be optimal for PNA₂DNA triplex stability and thus enhance strand-displacement binding to double-stranded DNA.

5

PNA058

N TTTCCCTTCCTTTT LLL TTTTCCTTCCTTTT C (SEQ ID NO 4)

Each PCR product (5 µg/ml) was incubated with each PNA probe (10 µg/ml), at 37°C in 0.5 X TE buffer (1 mM Tris.HCl, 0.1 mM EDTA, 10 5 mM NaCl, pH 8.0) for varying time intervals before the reaction was terminated by adding 150 mM HBS, pH 7.4 on ice. Samples were run on a non-denaturing 12% polyacrylamide gel. The electrophoretic mobility of the triplex PNA₂DNA was compared to the duplex DNA of the relevant PCR product and visualised by 15 EtBr staining. Triplex structures were observed suggesting that PNA can directly detect double-stranded PCR products.

The results of the gel retardation studies showed that single-stranded PNA did not strand invade the PCR products within the 20 first 60 minutes. (This is backed up in the literature where it has been demonstrated that the association of a bis-PNA with a single strand of homopurine DNA gives a complex that is significantly more stable than the one formed with two single PNA strands due to a more favourable entropy of reaction.)

25

Bis-PNA, however, formed a triplex within the first 10 minutes of reaction.

Example 2

30 Detection of triplexes on a surface plasmon resonance (SPR) surface.

Biotin labelled bis-PNA (50 µg/ml) was linked to a dextran surface (Biacore, SAchip) via a streptavidin-biotin interaction. A sample of both PCR products (10 µg/ml), in water, was flowed

over this sensor surface and were detected by a change in refractive index. The SPR system could differentiate between purine-rich and non-purine rich PCR products in near real time (See Figure 3).

Claims

1. A method for detecting the presence of a target nucleic acid sequence in a sample, said method comprising
 - 5 (a) amplifying said target nucleic acid so that the product of the amplification reaction includes a purine rich region,
 - (b) contacting the sample with a peptide nucleic acid able to bind to at least a portion of said target sequence; and
 - 10 (c) detecting the presence of triplex DNA structures.
2. A method according to claim 1 wherein the peptide nucleic acid is bis-PNA.
- 15 3. A method according to claim 1 or claim 2 wherein the amplification product is exposed to the peptide nucleic acid during or after the amplification reaction.
4. A method according to claim 3 wherein the amplification
 - 20 product is exposed to the peptide nucleic acid after completion of the amplification reaction.
5. A method according to any one of the preceding claims wherein the amplification reaction is a polymerase chain
 - 25 reaction.
6. A method according to any one of the preceding claims wherein the target nucleic acid contains a purine rich region.
- 30 7. A method according to any one of the preceding claims wherein a purine rich region is introduced into the amplification product during the amplification reaction.

8. A method according to claim 7 wherein primers used in the amplification comprise a plurality of pyrimidines at the 5' end thereof.

5 9. A method according to any one of the preceding claims wherein the peptide nucleic acid is immobilised on a support.

10. A method according to claim 9 wherein the support is a waveguide of a detection device.

10

11. A method according to claim 10 wherein the detection device is a surface plasmon resonance detector.

12. A method according to any one of claims 1 to 8 wherein the
15 triplex structure is detected by a gel retardation method.

13. A primer comprising a sequence which hybridises to an end region of a target nucleic acid sequence, and a plurality of pyrimidine residues at a 5' region thereof.

20

15. A kit for carrying out a method according to any one of the preceding claims, said kit comprising a peptide nucleic acid sequence which is specific for a target nucleotide sequence.

25 16. A kit according to claim 14 wherein the peptide nucleic acid is immobilised on a waveguide of an evanescent wave detector apparatus.

17. A kit according to claim 15 wherein the evanescent wave
30 detector apparatus is a surface plasmon resonance detector.

18. A kit according to any one of claims 15 to 17 which further comprises a primer according to claim 13.

19. A method for detecting a nucleotide sequence according to claim 1, substantially as hereinbefore described.


Abstract

A method for detecting the presence of a target nucleic acid sequence in a sample, said method comprising

- 5 (a) amplifying said target nucleic acid so that the product of the amplification reaction includes a purine rich region,
- (b) contacting the sample with a peptide nucleic acid able to bind to at least a portion of said target sequence; and
- 10 (c) detecting the presence of triplex DNA structures.


The detection is suitably effected directly, for example using a surface plasmon resonance detector.

Figure 1



THIS PAGE BLANK (USPTO)

Incorporation of Polypurine Stretches into PCR Product Using 5'-Tagging of Primers with Polypyrimidine Sequences



KEY:


[complementary to target] = Complementary to target

[5' - polypyrimidine tail (C, T)] = 5' - polypyrimidine tail (C, T)

THIS PAGE BLANK (USPTO)

3/3

Figure 3



PCT NO : 899 / 02317

Form 23/77 : 19 / 7 / 99

AGENT : D / I P R .

THIS PAGE BLANK (USPTO)

THIS PAGE BLANK (USPTO)

THIS PAGE BLANK (USPTO)



Creation date: 07-13-2004
Indexing Officer: MAUNG - MOE AUNG
Team: OIPEBackFileIndexing
Dossier: 09744489

Legal Date: 07-16-2001

No.	Doccode	Number of pages
1	FOR	82
2	FOR	46
3	NPL	2
4	NPL	8
5	NPL	4

Total number of pages: 142

Remarks:

Order of re-scan issued on

